Shift in Cancer Research Translation

September 2014. Companies offering cancer diagnostics or drugs abound. A few successful products are efficient and evidence attractive opportunities for profit-making, which fuel investors’ fantasies in turn. However translation of cancer research into a broader spectrum of tangible clinical results – paediatric or geriatric ones ¬ continues to fall short of high hopes.

Christof von Kalle, at the time Head of the National Center for Tumor Diseases (NCT) at Heidelberg provides a sense of how wishful wangling or group think lead up to dead ends in personalised medicine. What is at issue in research on checkpoint inhibitors, cancer stem cells, myelodysplastic syndromes, lung cancers or other tumours? How beneficial are the European Medicines Agency’s or the UK pharma’s initiatives to open up access to clinical trials data for R&D centres like NCT? What about French regulatory requirements? When does a hype of research about molecular cancer biomarkers achieve the opposite? An enriching perspective on delicate issues.Reading time: 26 min

Read Now:
1,50 EUR (incl. 7% VAT)

Back to section